SCM
IOVA icon

Soleus Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Soleus Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Sell
150,000
-850,000
-85% -$3.23M 0.02% 91
2026
Q1 		$3.51M Buy
+1,000,000
New +$3.2M 0.14% 73
2025
Q4 		– Sell
-976,707
Closed -$2.12M – 109
2025
Q3 		$2.12M Sell
976,707
-2,285,000
-70% -$5.4M 0.11% 73
2025
Q2 		$5.61M Sell
3,261,707
-4,523,293
-58% -$11.3M 0.37% 51
2025
Q1 		$25.9M Buy
7,785,000
+1,225,000
+19% +$6.32M 1.87% 16
2024
Q4 		$48.5M Sell
6,560,000
-1,968,500
-23% -$18.2M 3.05% 8
2024
Q3 		$80.1M Buy
8,528,500
+980,500
+13% +$9.29M 6.2% 2
2024
Q2 		$60.5M Buy
7,548,000
+4,043,000
+115% +$43.3M 5.34% 2
2024
Q1 		$51.9M Buy
3,505,000
+2,950,000
+532% +$34.3M 3.86% 4
2023
Q4 		$4.51M Sell
555,000
-684,777
-55% -$3.58M 0.5% 46
2023
Q3 		$5.64M Hold
1,239,777
– – 0.52% 49
2023
Q2 		$8.73M Sell
1,239,777
-210,000
-14% -$1.5M 0.97% 32
2023
Q1 		$8.86M Buy
+1,449,777
New +$10M 0.92% 30
2022
Q4 		– Sell
-1,025,200
Closed -$9.82M – 82
2022
Q3 		$9.82M Buy
1,025,200
+305,600
+42% +$3.52M 1.33% 25
2022
Q2 		$7.94M Buy
+719,600
New +$9.43M 1.24% 29

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Soleus Capital Management's IOVA Position: Q2 2026 in Review

Soleus Capital Management reduced its Iovance Biotherapeutics (IOVA) stake by 85% in Q2 2026, selling an estimated $3.23M and leaving 150,000 shares worth $624K. The position accounts for 0.02% of the portfolio, ranked #91.

Soleus Capital Management first reported a position in IOVA in Q2 2022 and has held it in 15 quarters since. The position peaked at $80.1M in Q3 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Soleus Capital Management held 150,000 shares of Iovance Biotherapeutics worth $624K as of Q2 2026.
  • Soleus Capital Management sold 850,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $3.23M.
  • Iovance Biotherapeutics made up 0.02% of Soleus Capital Management's portfolio in Q2 2026, its #91 holding.
  • Soleus Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 15 quarters since.
  • Soleus Capital Management's Iovance Biotherapeutics position peaked at $80.1M in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.